PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Paul Westberg Joins Versartis as Senior Vice President, Business Development
- Focus on Transactions for Novel Therapeutics –
View HTML
Toggle Summary Versartis to Present New Data at International Congress on Endocrinology
- Posters will Illustrate Progress of Company’s Drugs for Metabolic and Endocrine Diseases -
View HTML
Toggle Summary Versartis to Present at Biotech Showcase in San Francisco
– Company Focused on Extending the Half-Life of Drugs for Metabolic and Endocrine Diseases –
View HTML
Toggle Summary XTEN Data from Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum Half-life of Protein Therapeutics
XTEN Data from Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum Half-life of Protein Therapeutics Redwood City and Mountain View, CA  – November 15, 2009 – Amunix, Inc. and Versartis, Inc. announced today that the scientific journal Nature Biotechnology
View HTML
Toggle Summary Versartis Presents Preclinical Data for Novel Type 2 Diabetes Drug
New Compounds Extend Half-Life for Monthly Dosing
View HTML
Toggle Summary Versartis to Provide Update on Product Pipeline at Two Technology Conferences
New Technology Being Used to Extend Half-Life of Drugs for Metabolic and Endocrine Diseases
View HTML
Toggle Summary SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes AMSTERDAM, August 17 - SynCo Bio Partners, a Netherlands based biopharmaceutical contract manufacturer, and Versartis, Inc. today announced a strategic partnership to produce Versartis' lead drug candidate VRS-859, a novel
View HTML
Toggle Summary Versartis Presents Positive Preclinical Data on Two Product Candidates at ENDO 09
New Company Focusing on Extending Half-Life of Drugs for Metabolic and Endocrine Diseases
View HTML
Toggle Summary Versartis Publishes Preclinical Abstracts for Two Product Candidates at 2009 American Diabetes Association Scientific Sessions
New Company Focusing on Extending Half Life of Drugs for Metabolic and Endocrine Diseases
View HTML
Toggle Summary Versartis, Inc. Completes Series A Funding of $11 Million [€7.9 M] in a Joint Venture between Index Ventures and Amunix, Inc.
Versartis, Inc. Completes Series A Funding of $11 Million [€7.9 M] in a Joint Venture between Index Ventures and Amunix, Inc. Redwood City, CA – June 2, 2009 – Versartis, Inc. announced today that it has closed a Series A financing with an initial commitment of $11 million [€7.9 M] from Index
View HTML